Human papillomavirus (HPV) prevalence among men aged 19-27 years in the Netherlands.

• Conditions: HPV; human papillomavirus; 10002252

• Registration Number: NL-OMON53219
• Lead Sponsor: RIVM

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 9 April 2024

Recruitment & Eligibility

• Status: Pending
• Sex: Not specified
• Target Recruitment: 1495

Inclusion Criteria

- Male
- Born from 1996 up to and including 2003
- Provided informed consent

Exclusion Criteria

not applicable

Study & Design

• Study Type: Observational non invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>The primary study outcomes are the prevalence of genital hrHPV *overall* and<br /><br>types 16 and 18 and the HPV vaccination status after completion of the catch-up<br /><br>campaign. </p><br>

Secondary Outcome Measures

Name	Time	Method
<p>Secondary outcomes include the genital prevalences of HPV types other than<br /><br>types 16 and 18 as well as the prevalence of hrHPV in urine to compare the<br /><br>accuracy of hrHPV detection of self-collected first-void urine with<br /><br>self-collected penile swabs.</p><br>